心血管手术设备的全球市场，市场规模和占有率的分析 - 成长趋势，预测(2025年～2033年)

心血管外科手术设备市场趋势及总结

全球心血管手术器械市场规模预计将从 2024 年的 21.1 亿美元增至 2033 年的 28.6 亿美元，2025 年至 2033 年的复合年增长率为 3.45%。技术的快速进步、经济高效的技术的日益普及以及对微创手术的需求不断增长是该市场的主要驱动力。

推动心血管外科器械市场成长的因素

心血管疾病发生率不断上升

心血管设备市场的主要成长动力之一是心臟衰竭和冠状动脉疾病（CAD）等慢性心血管疾病的发生率不断上升。冠状动脉支架或心臟支架是最重要的心血管装置之一。这些设备有助于治疗心房颤动、冠状动脉疾病、心臟病和动脉狭窄等致命的心臟病。心臟病发病率的上升推动了全球对先进心臟设备的需求。

根据美国疾病管制与预防中心（CDC）2023年11月发布的数据，2022年美国成年人中有4.9%被诊断出患有冠心病。此外，心血管疾病将在 2022 年导致 695,547 人死亡，成为美国第一大死因。世界卫生组织（WHO）估计，心臟病每年夺走1,790万人的生命。

此外，市场扩张很大程度上归功于监管机构对创新设备的批准不断增加。在预测期内，市场可能会受到国家机构采取的众多举措的推动，这些举措旨在使发展中国家更广泛的人群能够使用心血管设备。

增加获得有效设备的机会

全球心臟病盛行率明显上升，推动了对有效心臟装置的需求。这些国家之所以采用新技术，是因为这些技术易于普及。为满足新兴市场对这些设备日益增长的需求而采取的措施也推动了市场的发展。此外，投资者也致力于增加中国、墨西哥和印度等国家获得负担得起的心血管设备的机会。因此，预计未来几年它将占据心血管设备市场的巨大占有率。

例如，UltraLinQ Healthcare Solutions 在 2023 年 1 月的阿拉伯健康 2023 会议上推出了新的心臟监测解决方案。它是一个端到端的系统，使医院和专科诊所能够为前往诊所或在家中远端存取的患者提供 Holter 服务。

微创技术的应用日益广泛

推动市场扩张的主要因素之一是微创技术在心血管外科手术的应用日益广泛。与开放式手术相比，微创技术具有许多优势，包括使用复杂的影像、机器人辅助和更少的切口。患者可受益于更快的恢復时间、更少的不适、更少的感染机会和更少的併发症。由于患者偏好微创手术，对支架、导管和机器人手术器械等先进心血管设备的需求激增。此外，微创手术对患者和医疗保健专业人员具有吸引力，因为它可以更早出院、降低医疗成本并缩短治疗时间。随着微创心臟手术的趋势和技术的不断进步，心血管手术设备市场预计将进一步以更快的速度成长。

心血管外科市场的课题

设备成本高

该行业面临的主要障碍之一是起搏器、支架和机器人手术工具等先进心血管设备的成本高昂。这些设备需要大量製造和研发投入，这增加了成本。这些成本障碍限制了这些设备的使用，特别是在医疗预算匮乏的中低收入地区。心血管护理方面的差异可能是由于某些地区的患者无法获得最新、最有效的药物。此外，即使结果有所改善，这些地区的医疗保健提供者也可能难以索取费用。製造商、政府和卫生系统必须考虑具有成本效益的替代方案、降价策略和创造性的融资方法，以改善获取途径并使这些技术更为广泛地普及且价格更为实惠。

本报告研究了全球心血管外科设备市场，并提供了成长动力和课题、每个细分市场的分析以及关键公司的分析。

目录

第1章 简介

第2章 调查手法

第3章 摘要整理

第4章 市场动态

• 成长促进因素
• 课题

第5章 心血管手术设备市场

第6章 市场占有率

• 各产品类型
• 各用途
• 各终端用户
• 各国

第7章 产品类型

• 心臟不停跳手术系统
• 人工心肺
• 心导管电气烧灼术设备
• 抛弃式灌挪用品

第8章 用途

• 先天性心臟病
• 心律不整
• 冠状动脉疾病
• 充血性心臟衰竭
• 其他

第9章 终端用户

• 医院
• 门诊病人手术中心
• 其他

第10章 国家

• 北美
  • 美国
  • 加拿大
• 欧洲
  • 法国
  • 德国
  • 义大利
  • 西班牙
  • 英国
  • 比利时
  • 荷兰
  • 土耳其
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 韩国
  • 泰国
  • 马来西亚
  • 印尼
  • 澳洲
  • 纽西兰
• 南美
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东·非洲
  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 南非

第11章 波特的五力分析

第12章 SWOT分析

第13章 主要企业的分析

• Abbott Laboratories
• Boston Scientific Corporation
• Edwards Lifesciences
• Cardinal Health Inc.
• Medtronic PLC
• GE Healthcare
• LivaNova PLC
• Terumo Corporation

Cardiovascular Surgical Devices Market Trends & Summary

Cardiovascular Surgical Devices market is expected to reach US$ 2.86 billion by 2033 from US$ 2.11 billion in 2024, with a CAGR of 3.45% from 2025 to 2033. Rapid technological advancement, an increase in reasonably priced and efficient technologies, and growing demand for minimally invasive procedures are the primary factors propelling this market.

The report Cardiovascular Surgical Devices Market & Forecast covers by Product Type (Beating Heart Surgery Systems, Cardiopulmonary Bypass Equipment, Cardiac Ablation Devices, Perfusion Disposable), Application (Congenital Heart Defects, Cardiac Arrhythmia, Coronary Heart Disease, Congestive Heart Failure, Others), End-User (Hospitals, Ambulatory Surgical Centers, Others), Country and Company 2025-2033.

Cardiovascular Surgical Devices Industry Overview

The medical equipment and technologies used in the diagnosis, treatment, and management of heart-related illnesses, including arrhythmias, heart valve problems, and coronary artery disease, are the main focus of the cardiovascular surgical devices sector. Stents, heart valves, bypass grafts, pacemakers, defibrillators, and surgical tools are among the main goods. The growing incidence of cardiovascular diseases as a result of aging populations, sedentary lifestyles, and poor diets are some of the factors driving market expansion. Robotic-assisted operations and minimally invasive procedures are examples of technological advancements that have improved patient outcomes while cutting recovery times and medical expenses. Government funding, improvements in diagnostics, and growing healthcare awareness all support industry growth. High expenses, legal restrictions, and the demand for continuous clinical research to improve device efficacy and safety provide difficulties for the sector.

One of the most common illnesses in the world is cardiovascular disease. Cardiovascular disease (CVD) was the top cause of mortality in the United States in January 2024, accounting for 931,578 fatalities, more than all malignancies and chronic respiratory diseases combined, according to the American Heart Association. Cardiovascular devices are therefore essential for precisely identifying and treating heart conditions, which supports market growth. Rapid technological advancement, an increase in reasonably priced and efficient technologies, and growing demand for minimally invasive procedures are the primary factors propelling this market.

The market is expanding as a result of the rise in chronic cardiovascular disease cases. The need for cardiovascular devices has grown as a result of a rise in cardiovascular diseases. One of the most important cardiovascular devices is a heart or coronary artery stent. They make it easier to treat heart conditions such heart attacks, coronary disease, atrial fibrillation, and the growth of clogged arteries that are thought to pose a major risk to life. According to a WHO analysis from May 2024, cardiovascular diseases (CVDs) account for over 42.5% of all deaths in Europe each year, or almost 10,000 deaths per day, making them the leading cause of disability and early death. Men are over 2.5 times more likely than women to die from cardiovascular diseases (CVDs), and young people in Eastern Europe and Central Asia (ages 30-69) are at approximately five times the risk of dying from these diseases than their counterparts in Western Europe.

Growth Drivers for the Cardiovascular Surgical Devices Market

Increase in Cardiovascular Disease Prevalence

Plywood's In terms of expenses and medical services, the most common cause of patient growth is heart disease. One of the main factors driving the growth of the cardiovascular devices market is the increase in the prevalence of chronic cardiovascular illnesses like heart failure and coronary artery disease (CAD). Coronary or cardiac stents are among the most important cardiovascular devices. These devices aid in the treatment of potentially fatal cardiac problems, including atrial fibrillation, coronary heart disease, heart attacks, and constricted artery opening. The global need for sophisticated cardiac devices is increased by the frequency of cardiac disorders.

According to Centers for Disease Control and Prevention (CDC) data released in November 2023, 4.9% of adults in the United States received a coronary heart disease diagnosis in 2022. Additionally, cardiovascular illnesses account for 695,547 fatalities in 2022, making them the leading cause of death in the United States. The World Health Organization estimates that heart disease claims 17.9 million lives annually.

Furthermore, the market's expansion is significantly aided by the rise in regulatory bodies' approvals of innovative gadgets. The market will likely be guided over the forecast period by a number of efforts implemented by state bodies to make cardiovascular devices available to a broad population in developing regions.

Growing Accessibility of Effective Devices

The need for effective heart devices is fueled by the apparent rise in the prevalence of heart illnesses worldwide. The adoption of modern technology in these countries can be attributed to their accessibility. The market has also been stimulated by initiatives that have been implemented to meet the growing demand for these devices in emerging markets. Additionally, investors are concentrating on increasing the accessibility of affordable cardiovascular equipment in nations like China, Mexico, India, and others. In consequence, this is anticipated to draw a significant portion of the market for cardiovascular devices in the years to come.

For example, UltraLinQ Healthcare Solutions debuted a new cardiac monitoring solution at the Arab Health 2023 conference in January 2023. It has an end-to-end system that enables hospitals and specialty clinics to provide Holter services to patients who visit their clinics or who can be accessed remotely at home.

Rising Adoption of Minimally Invasive Techniques

One major factor propelling the market's expansion is the growing use of minimally invasive procedures in cardiovascular surgery. Compared to open operations, these techniques have a number of benefits, including the use of sophisticated imaging, robotic help, and fewer incisions. Patients gain from shorter recovery periods, less discomfort, a decreased chance of infection, and fewer complications. The need for sophisticated cardiovascular devices like stents, catheters, and robotic surgical instruments has surged as a result of patients' growing preference for minimally invasive operations. Furthermore, minimally invasive procedures are more appealing to patients and healthcare professionals since they enable faster hospital discharge, lower medical expenses, and shorter treatment durations overall. The market for cardiovascular surgical equipment is anticipated to grow even faster as a result of the trend toward minimally invasive cardiac procedures and ongoing technological advancements.

Challenges in the Cardiovascular Surgical Devices Market

High Cost of Devices

One major obstacle in the industry is the high cost of sophisticated cardiovascular equipment, such as pacemakers, stents, and robotic surgical instruments. The cost of these gadgets rises because they frequently need significant investment in manufacturing, research, and development. Their accessibility is restricted by this cost barrier, especially in areas with low and intermediate incomes where healthcare budgets are tight. Disparities in cardiovascular care may result from patients in certain areas not having access to the newest, most efficient medicines. Furthermore, even with better results, healthcare practitioners in these areas might find it difficult to defend the cost. Manufacturers, governments, and healthcare systems must investigate cost-effective substitutes, price-cutting tactics, and creative financing methods to increase access and make these technologies more generally accessible and reasonably priced.

Regulatory and Compliance Hurdles

The market for cardiovascular surgical devices is severely hampered by regulatory and compliance issues. New device approval is frequently a drawn-out procedure that necessitates comprehensive clinical trials to prove long-term results, safety, and effectiveness. Authorities like the FDA, EMA, or other national agencies have strict regulations that manufacturers must follow. These regulations differ depending on the region. These specifications may lengthen product launch schedules, postponing market entry and reducing potential profits. Development costs may also be raised by the price of carrying out clinical trials, obtaining required data, and satisfying regulatory requirements. These obstacles could hinder innovation, particularly for smaller businesses with fewer resources, and delay the adoption of ground-breaking innovations that could enhance cardiovascular care outcomes for patients.

Cardiac arrhythmia drives demand for devices like pacemakers and defibrillators

Cardiac arrhythmia is pivotal in the cardiovascular surgical devices market because of its prevalence and life-threatening implications. This spurs demand for modern solutions like pacemakers and catheter ablation structures. For instance, in 2024, Boston Scientific Corporation received FDA approval for the FARAPULSE(TM) Pulsed Field Ablation (PFA) System, offering a unique technique for treating drug-refractory, recurrent, symptomatic, paroxysmal atrial fibrillation.

United States Cardiovascular Surgical Devices Market

The high prevalence of cardiovascular diseases (CVDs), an aging population, and growing awareness of heart health are the main factors driving the United States' cardiovascular surgical devices industry, which is among the biggest and most developed in the world. Devices for arrhythmias, heart valve problems, and coronary artery disease, such as pacemakers, defibrillators, robotic surgical instruments, and stents, are important market segments. Technological developments that improve patient outcomes and shorten recovery times, such as bioresorbable devices and minimally invasive operations, are driving market expansion. The adoption of cutting-edge equipment is also made easier in the United States by its well-established healthcare infrastructure, government support, and high healthcare spending rate. High gadget costs, difficulties with regulations, and problems with reimbursement, however, continue to be commercial obstacles. The US continues to be a major force behind the development and marketing of cardiovascular devices worldwide.

An American Heart Association report from January 2024 states that around 2,552 fatalities in the United States are caused by CVD per day. Because of the substantial impact that CVD has on public health, there is an urgent need for efficient management and treatment options in the US market.

Abbott introduced the Abbott HeartMates program in October 2023 to help heart patients by allowing them to connect with others experiencing similar heart health concerns and share their stories. Professional football player Damar Hamlin served as the company's first ambassador at the beginning of the campaign under this program.

Germany Cardiovascular Surgical Devices Market

Due to its sophisticated healthcare system, elderly population, and high prevalence of cardiovascular diseases (CVDs), Germany is one of Europe's largest markets for cardiovascular surgical equipment. The adoption of sophisticated cardiovascular equipment, including as pacemakers, heart valves, stents, and surgical robots, is facilitated by the nation's robust reimbursement regulations and well-established medical infrastructure. Germany's emphasis on innovation, bolstered by a robust research and development environment, makes it easier to introduce innovative technology such as bioresorbable devices and minimally invasive procedures. The market is also growing as a result of the rising need for therapies for arrhythmias, heart failure, and coronary artery disease. Strict regulatory standards, the expensive cost of sophisticated gadgets, and rivalry from other European nations are some of the market's obstacles, nevertheless. Germany is nevertheless a major player in the global market for cardiovascular surgical devices in spite of these obstacles.

Data from a German registry for 2023, which included 168,841 cardiac and vascular surgeries in 77 institutions, was published in January 2024 by The Journal of Thoracic and Cardiovascular Surgery. The unadjusted in-hospital survival rates for 28,996 coronary artery bypass grafts, 39,859 cardiac valve surgeries, and 19,699 pacemaker/ICD implants were 97.6%, 97.7%, and 99.2%, respectively. In addition, 324 heart transplants and 2,982 extracorporeal life support treatments were carried out.

India Cardiovascular Surgical Devices Market

The increasing prevalence of cardiovascular diseases (CVDs) and improved access to healthcare are driving the market for cardiovascular surgical devices in India. Heart disease is becoming more prevalent in the nation as a result of aging populations, urbanization, and shifting lifestyles. Government programs, growing public awareness of heart health, and the development of healthcare infrastructure are important market drivers. Particularly in urban areas, there is a growing need for cardiovascular equipment such as heart valves, pacemakers, stents, and angioplasty instruments. Additionally, as doctors and patients look for better results and faster recovery periods, the use of minimally invasive procedures is increasing. However, obstacles including exorbitant equipment expenses, restricted reimbursement, and restricted availability in remote regions may prevent the industry from growing further. India continues to be a promising market for producers of cardiovascular devices in spite of these obstacles.

In the Indian state of Maharashtra, a decrease in the cost of coronary stents resulted in a 43.0% rise in the number of heart procedures performed, according a study conducted by the Harvard T.H. Chan School of Public Health (HSPH).

Saudi Arabia Cardiovascular Surgical Devices Market

Due to the high prevalence of cardiovascular diseases (CVDs) and significant healthcare investments, the market for cardiovascular surgical equipment is growing quickly in Saudi Arabia. An aging population, sedentary lifestyles, and changing lifestyles are the main causes of the Kingdom's rising heart disease rates. The government's Vision 2030 program, which aims to improve medical technology, expand access to high-quality care, and strengthen healthcare infrastructure, is driving up demand for sophisticated cardiovascular devices like heart valves, pacemakers, defibrillators, and stents. Furthermore, the industry is expanding more quickly due to consumers' increasing preference for minimally invasive procedures. Widespread adoption may be hampered by issues including exorbitant device costs, a lack of local manufacturing, and the requirement for specialized training for sophisticated treatments. Saudi Arabia is still a major Middle Eastern market for cardiovascular surgical devices in spite of this.

The BMC Cardiovascular Diseases article from March 2024 states that 1.6% of Saudi Arabians aged 15 and older had cardiovascular disease. This statistic shows the proportion of people in this age group who suffer from heart disease and other cardiovascular diseases of various kinds. The information highlights an important facet of the nation's health profile and sheds light on the prevalence of cardiovascular diseases among Saudi Arabians.

Cardiovascular Surgical Devices Market Segments

Product Type - Market breakup in 4 viewpoints:

1. Beating Heart Surgery Systems

2. Cardiopulmonary Bypass Equipment

3. Cardiac Ablation Devices

4. Perfusion Disposable

Application - Market breakup in 5 viewpoints:

1. Congenital Heart Defects

2. Cardiac Arrhythmia

3. Coronary Heart Disease

4. Congestive Heart Failure

5. Others

End-User - Market breakup in 3 viewpoints:

1. Hospitals

2. Ambulatory Surgical Centers

3. Others

Country - Market of 25 Countries Covered in the Report:

1. North America

• 1.1 United States
• 1.2 Canada

2. Europe

• 2.1 France
• 2.2 Germany
• 2.3 Italy
• 2.4 Spain
• 2.5 United Kingdom
• 2.6 Belgium
• 2.7 Netherland
• 2.8 Turkey

3. Asia Pacific

• 3.1 China
• 3.2 Japan
• 3.3 India
• 3.4 South Korea
• 3.5 Thailand
• 3.6 Malaysia
• 3.7 Indonesia
• 3.8 Australia
• 3.9 New Zealand

4. Latin America

• 4.1 Brazil
• 4.2 Mexico
• 4.3 Argentina

5. Middle East & Africa

• 5.1 Saudi Arabia
• 5.2 UAE
• 5.3 South Africa

All the Key players have been covered from 3 Viewpoints:

• Overview
• Recent Development
• Revenue Analysis

Company Analysis:

1. Abbott Laboratories

2. Boston Scientific Corporation

3. Edwards Lifesciences

4. Cardinal Health Inc.

5. Medtronic PLC

6. GE Healthcare

7. LivaNova PLC

8. Terumo Corporation

Key Questions Answered in Report:

1. How big is the Cardiovascular Surgical Devices industry?

The global Cardiovascular Surgical Devices market size was valued at US$ 2.11 billion in 2024 and is expected to reach US$ 2.86 billion in 2033.

2. What is the Cardiovascular Surgical Devices growth rate?

The global Cardiovascular Surgical Devices market is expected to expand at a compound annual growth rate (CAGR) of 3.45% from 2025 to 2033.

3. Who are the key players in Cardiovascular Surgical Devices industry?

Some key players operating in the Cardiovascular Surgical Devices market includes Abbott Laboratories, Boston Scientific Corporation, Edwards Lifesciences, Cardinal Health Inc., Medtronic PLC, GE Healthcare, LivaNova PLC, and Terumo Corporation.

4. What are the factors driving the Cardiovascular Surgical Devices industry?

Ageing populations, rising rates of heart disease, technological developments, minimally invasive procedures, government funding for healthcare, increased public awareness of healthcare issues, and the need for better patient outcomes and surgical efficiency are all factors driving the cardiovascular surgical devices market.

5. Which Region held the largest market share in the Cardiovascular Surgical Devices industry?

North America is expected to hold the largest market share in the industry.

6. What segments are covered in the Cardiovascular Surgical Devices Market report?

Product Type, Application, End User and Countries segment are covered in this report.

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenges

5. Cardiovascular Surgical Devices Market

6. Market Share

• 6.1 By Product Type
• 6.2 By Application
• 6.3 By End User
• 6.4 By Countries

7. Product Type

• 7.1 Beating Heart Surgery Systems
• 7.2 Cardiopulmonary Bypass Equipment
• 7.3 Cardiac Ablation Devices
• 7.4 Perfusion Disposable

8. Application

• 8.1 Congential Heart Defects
• 8.2 Cardiac Arrthymia
• 8.3 Coronary Heart Disease
• 8.4 Congestive Heart Failure
• 8.5 Others

9. End User

• 9.1 Hospitals
• 9.2 Ambulatory Surgical Centers
• 9.3 Others

10. Countries

• 10.1 North America
  • 10.1.1 United States
  • 10.1.2 Canada
• 10.2 Europe
  • 10.2.1 France
  • 10.2.2 Germany
  • 10.2.3 Italy
  • 10.2.4 Spain
  • 10.2.5 United Kingdom
  • 10.2.6 Belgium
  • 10.2.7 Netherland
  • 10.2.8 Turkey
• 10.3 Asia Pacific
  • 10.3.1 China
  • 10.3.2 Japan
  • 10.3.3 India
  • 10.3.4 South Korea
  • 10.3.5 Thailand
  • 10.3.6 Malaysia
  • 10.3.7 Indonesia
  • 10.3.8 Australia
  • 10.3.9 New Zealand
• 10.4 Latin America
  • 10.4.1 Brazil
  • 10.4.2 Mexico
  • 10.4.3 Argentina
• 10.5 Middle East & Africa
  • 10.5.1 Saudi Arabia
  • 10.5.2 UAE
  • 10.5.3 South Africa

11. Porter's Five Forces Analysis

• 11.1 Bargaining Power of Buyers
• 11.2 Bargaining Power of Suppliers
• 11.3 Degree of Rivalry
• 11.4 Threat of New Entrants
• 11.5 Threat of Substitutes

12. SWOT Analysis

• 12.1 Strength
• 12.2 Weakness
• 12.3 Opportunity
• 12.4 Threat

13. Key Players Analysis

• 13.1 Abbott Laboratories
  • 13.1.1 Overview
  • 13.1.2 Recent Development
  • 13.1.3 Revenue Analysis
• 13.2 Boston Scientific Corporation
  • 13.2.1 Overview
  • 13.2.2 Recent Development
  • 13.2.3 Revenue Analysis
• 13.3 Edwards Lifesciences
  • 13.3.1 Overview
  • 13.3.2 Recent Development
  • 13.3.3 Revenue Analysis
• 13.4 Cardinal Health Inc.
  • 13.4.1 Overview
  • 13.4.2 Recent Development
  • 13.4.3 Revenue Analysis
• 13.5 Medtronic PLC
  • 13.5.1 Overview
  • 13.5.2 Recent Development
  • 13.5.3 Revenue Analysis
• 13.6 GE Healthcare
  • 13.6.1 Overview
  • 13.6.2 Recent Development
  • 13.6.3 Revenue Analysis
• 13.7 LivaNova PLC
  • 13.7.1 Overview
  • 13.7.2 Recent Development
  • 13.7.3 Revenue Analysis
• 13.8 Terumo Corporation
  • 13.8.1 Overview
  • 13.8.2 Recent Development
  • 13.8.3 Revenue Analysis